Investing.com - ProQR Therapeutics NV (NASDAQ: PRQR) reported third quarter EPS of €-0.070, €0.02 better than the analyst estimate of €-0.086. Revenue for the...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Chamath Palihapitiya, 10% Owner at ProKidney (NASDAQ:PROK), reported a large insider sell on October 24, according to a new...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Chamath Palihapitiya, 10% Owner at ProKidney (NASDAQ:PROK), reported a large insider sell on October 11, according to a new...
Benzinga - by Vandana Singh, Benzinga Editor. BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing...
Benzinga - by Lisa Levin, Benzinga Editor. The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a...
Investing.com - ProQR Therapeutics NV (NASDAQ: PRQR) reported second quarter EPS of €-0.100, €0.01 better than the analyst estimate of €-0.111. Revenue for the...
Investing.com - ProQR Therapeutics NV (NASDAQ: PRQR) reported first quarter EPS of €-0.110, better than the analyst estimate of €-0.119. Revenue for the quarter came in...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced...